bleomycin + cyclophosphamide + dactinomycin

This is a combination chemotherapy regimen consisting of three cytotoxic agents—bleomycin, cyclophosphamide, and dactinomycin (also known as actinomycin D)—used primarily in the treatment of various malignancies. - **Bleomycin** is a glycopeptide antibiotic derived from *Streptomyces verticillus* that binds to DNA and causes strand breaks through free radical formation, leading to inhibition of DNA synthesis and cell death[1]. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands by adding alkyl groups to the guanine base of DNA, resulting in impaired replication and apoptosis; it also has immunosuppressive properties[6][8]. - **Dactinomycin (Actinomycin D)** intercalates into DNA at the transcription initiation complex and prevents RNA synthesis by inhibiting RNA polymerase activity[5]. This combination may be used for cancers such as lymphomas (including Hodgkin's disease), sarcomas (e.g., rhabdomyosarcoma), germ cell tumors (testicular cancer), Wilms tumor, choriocarcinoma, ovarian cancer, cervical cancer, among others. The regimen leverages different mechanisms of action for synergistic antitumor effects.

Other names

博莱霉素 + 环磷酰胺 + 放线菌素Dbleomycin + cyclophosphamide + actinomycin D